[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100361316":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":65,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":32,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":32,"enrollmentInfo":80,"targetDuration":32,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Mclean Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cannabidiol Treatment Arm","EXPERIMENTAL","High-CBD sublingual product administered three times daily for the treatment period.",[13],"Drug: Cannabidiol",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Treatment Arm","PLACEBO_COMPARATOR","Placebo sublingual product administered three times daily for the treatment period.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cannabidiol","High-CBD, low-THC sublingual product formulated in palm oil",[9],[27],"CBD",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Staci Gruber, Ph.D.","PRINCIPAL_INVESTIGATOR",[38,42],{"name":35,"role":39,"phone":40,"phoneExt":32,"email":41},"CONTACT","617-855-2762","gruber@mclean.harvard.edu",{"name":43,"role":39,"phone":44,"phoneExt":32,"email":45},"Rosie Smith, M.S.","617-855-3338","cbdstudy@mclean.harvard.edu",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"McLean Hospital","RECRUITING","Belmont","Massachusetts","02478","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-71.17867,42.39593,{"lat":59,"lon":58},[62,64],{"name":63,"role":39,"phone":40,"phoneExt":32,"email":41},"Staci Gruber, PhD.",{"name":43,"role":39,"phone":44,"phoneExt":32,"email":45},{"type":66,"investigatorFullName":35,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","Director, Marijuana Investigations for Neuroscientific Discovery; Director, Cognitive and Clinical Neuroimaging Core; Associate Professor of Psychiatry, Harvard Medical School",[69],{"name":70,"class":71},"Etheridge Foundation","UNKNOWN","100361316","phase-2-pain-a-project-assessing-the-impact-of-a-novel-cannabinoid-product-100361316",false,"NCT03984565","PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product","Inclusion Criteria:\n\n* Subject has provided informed consent\n* Subject is 21 or older\n* Subject is fluent in English\n* Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.\n\nExclusion Criteria:\n\n* Non-fluent English speakers\n* Estimated IQ \\\u003C 75\n* A history of head injury or loss of consciousness greater than 5 minutes\n* Currently uses CBD products regularly\n* Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding\n* Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper\u002Fhypotension, cardiac disorders), or neurological disorder (including seizure disorder)\n* Primary neuropathic pain or cancer-related pain; patients experiencing neuropathic pain secondary to musculoskeletal pain will be allowed to enter the study\n* Disclosure of a genetic polymorphism affecting CYP2C9 function","ALL","21 Years",{"count":81,"type":82},25,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.",[88],"Chronic Pain",[23,90,91],"Medical Cannabis","Industrial Hemp","2026-03-24",{"date":94,"type":95},"2026-03-30","ACTUAL",{"date":97,"type":95},"2024-06-27",{"date":99,"type":82},"2026-09",{"name":35,"class":6},1]